From direcdy observed therapy to Accompagnateurs: Enhancing AIDS treatment outcomes in Haiti and in Boston

Clinical Infectious Diseases

Volumn 38, Issue SUPPL. 5, 2004, Pages

  Behforouz, H L ^a   Farmer, P E ^b   Mukherjee, J S ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; TUBERCULOSTATIC AGENT; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DIRECTLY OBSERVED THERAPY; DISEASE TRANSMISSION; DRUG COST; HAITI; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH PROMOTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MEDICAL STAFF; PATIENT CARE; PATIENT COMPLIANCE; PILOT STUDY; POVERTY; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; RURAL AREA; SIDE EFFECT; SOCIAL STATUS; SOCIAL SUPPORT; SOCIAL WORK; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; UNITED STATES; ANTIBIOTIC RESISTANCE; ARTICLE; COMMUNITY CARE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; BOSTON; COMMUNITY HEALTH SERVICES; DELIVERY OF HEALTH CARE; DIRECTLY OBSERVED THERAPY; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, VIRAL; HAITI; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; PILOT PROJECTS; POVERTY; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 2942586893     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/421408     Document Type: Review

References (34)

1. World Health Organization (WHO). Adherence to long-term therapies: evidence for action. Geneva: WHO, 2003.
2. Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med 2000; 50:1599-605.
3. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
4. Bedell SE, Jabbour S, Goldberg R, et al. Discrepancies in the use of medications: their extent and predictors in an outpatient practice. Arch Intern Med 2000; 160:2129-34.
5. Lerner BH, Gulikc RM, Dubler NN. Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease. Ann Intern Med 1998; 129:573-8.
6. Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. The rational clinical examination: is this patient taking the treatment as prescribed? JAMA 1993; 269:2779-81.
7. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30:S171-6.
8. Bangsberg DR, Hecht FM, Clague H, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26:435-42.
9. Sumartojo E. When tuberculosis treatment fails: a social behavioral account of patient adherence. Am Rev Respir Dis 1993; 147:1311-20.
10. Addington WW. Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States. Chest 1979; 76(suppl 6):741-53.
11. World Health Organization. WHO report on the tuberculosis epidemic. Geneva: World Health Organization, 1997.
12. Farmer P, Bayona J, Becerra M, et al. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis 1998; 2:869-76.
13. Farmer P, Kim JY. Community-based approaches to the control of multidrug-resistant tuberculosis: introducing "DOTS-plus." BMJ 1998; 317:671-4.
14. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348:119-28.
15. Gupta R, Kim JY, Espinal MA, et al. Responding to market failures in tuberculosis control. Science 2001; 293:1049-51.
16. Blower S, Farmer P. Predicting the public health impact of antiretrovirals: preventing HIV in developing countries. AIDScience 2003; 3 [online]. Available at: http://www.aidscience.org/Articles/AIDScience033.asp. Accessed 3 May 2004.
17. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-9.
18. Gupta R, Cegielski JP, Espinal MA, et al. Increasing transparency in partnerships for health - introducing the Green Light Committee. Trop Med Int Health 2002; 7:970-6.
19. United Nations Development Programme. Human development report 2003. New York: Oxford University Press, 2003.
20. United Nations Food and Agriculture Organization (FAO). The state of food insecurity in the world. Rome: FAO, 2003. Available at: http://www.fao.org/ docrep/006/j0083e/j0083e00.htm. Accessed 3 May 2004.
21. Joint United Nations Programme on HIV/AIDS (UNAIDS). Epidemiological fact sheets on HIV/AIDS and sexually transmitted infections: Haiti. 2002 Update. UNAIDS. Available at http://www.who.int/em-c-hiv/fact_sheets/All_countries.html. Accessed 3 May 2004.
22. Farmer P, Robin S, Ramilus SL, KiM JY. Tuberculosis, poverty, and "compliance": lessons from rural Haiti. Semin Respir Infect 1991; 6:254-60.
23. Farmer PE. Ethnography, social analysis, and the prevention of sexually transmitted HIV infection. In: Inhorn M, Brown P, eds. The anthropology of infectious disease. Amsterdam: Gordon and Breach, 1997:413-38.
24. Farmer P. Letter from Haiti. AIDS Clin Care 1997; 9:83-5.
25. Farmer P, Léandre F, Mukherjee JS, et al. Community-based approaches to HlV treatment in resource-poor settings. Lancet 2001; 358:404-9.
26. Farmer P, Léandre F, Mukherjee J, Gupta R, Tarter L, Kim JY. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull World Health Organ 2001; 79:1145-51.
27. Kim JY, Shakow A, Castro A, Vanderwarker C, Farmer P. Tuberculosis control. In: Smith R, Beaglehole R, Woodward D, Drager N, eds. Global public goods for health. New York: Oxford University Press, 2003: 55-72.
28. Sweetland A, Acha J, Guerra D. Enhancing adherence: the role of group psychotherapy in the treatment of multidrug-resistant tuberculosis in urban Peru. In: Cohen A, Kleinman A, Saraceno BE, eds. The world mental health casebook: social and mental health programs in low-income countries. New York: Kluwer Academic, 2002:51-79.
29. Smith Fawzi MC, Lambert W, Singler JM, et al. Prevalence and risk factors of STDs in rural Haiti: implications for policy and programming in resource-poor settings. Int J STD AIDS 2003; 14:848-53.
30. Farmer P, Léandre F, Koenig S, et al. Preliminary outcomes of directly-observed treatment of advanced HIV disease with ARVs (DOT-HAART) in rural Haiti [abstract 171]. In: Program and abstracts of the 10th Annual Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retroviruses and Human Health, 2003:120. Available at http://www.retroconference.org/2003/Abstract/Abstract.aspx?AbstractID=2135. Accessed 3May 2004.
31. Farmer PE, Léandre F, Bayona J, Louissant M. DOTS-Plus for the poorest of the poor: the Partners In Health experience in Haiti [abstract]. Int J Tuberc Lung Dis 2001;5:S257.
32. Behforouz HL, Kalmus A, Scherz CS, Kahn JS, Kadakia MB, Farmer PE. Directly observed therapy for HIV antiretroviral therapy in an urban US setting. J Acquir Immune Defic Syndr 2004; 36:642-5.
33. Mukherjee JS, Farmer PE, Niyizonkiza D, et al. Tackling HIV in resource poor countries. BMJ 2003; 327:1104-6.
34. Farmer P. Prevention without treatment is not sustainable. National AIDS Bulletin (Australia) 2000; 13:6-9.